Want to see TSE:TELO full AI Analyst Report?
TELO Stock Chart & Stats
C$0.04
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.04
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.10
Previous CloseN/A
Volume32.49K
Average Volume (3M)29.30K
Market Cap
C$4.52M
Enterprise ValueC$5.86M
Total Cash (Recent Filing)C$975.48K
Total Debt (Recent Filing)C$1.32M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding100,430,470
10 Day Avg. Volume22,350
30 Day Avg. Volume29,304
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)18.74
Price to Sales (P/S)0.00
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Telomere Diagnostics PlatformTeloView is a focused, platform-level product based on telomere biology. A durable, differentiated measurement technology can create barriers to entry, enable recurring service or licensing revenues, and support long-term product extension across applications.
Dual Research And Clinical Market ApplicabilityServing both research and clinical users diversifies potential revenue channels and demand drivers. Structural growth in oncology and age-related disease diagnostics supports multi-year adoption opportunities for a validated telomere platform.
Lean Operating FootprintA very small headcount implies lower fixed overhead and a lean R&D cost base, which can extend runway for pre-revenue firms. Sustained low structural costs help preserve capital while pursuing commercialization milestones.
Bears Say
No Revenue / Persistent Net LossesThe company remains pre-revenue with TTM losses near $2.34M, which undermines earnings visibility and increases execution risk. Without durable revenue, commercialization and scale depend on successful product adoption or continued external funding.
Deteriorated Balance Sheet And Rising LeverageNegative equity paired with new debt materially reduces financial flexibility. Higher leverage while assets are modest limits ability to absorb setbacks and raises refinancing or covenant risks absent sustained cash inflows.
Consistent Negative Operating And Free Cash FlowOngoing cash burn with negative operating and free cash flow erodes runway and necessitates external financing. Structural cash deficits make long-term funding cadence a key determinant of commercialization and scale prospects.
Telo Genomics Corp News
TELO FAQ
What was Telo Genomics Corp’s price range in the past 12 months?
Telo Genomics Corp lowest stock price was C$0.04 and its highest was C$0.10 in the past 12 months.
What is Telo Genomics Corp’s market cap?
Telo Genomics Corp’s market cap is C$4.52M.
When is Telo Genomics Corp’s upcoming earnings report date?
Telo Genomics Corp’s upcoming earnings report date is Nov 02, 2026 which is in 91 days.
How were Telo Genomics Corp’s earnings last quarter?
Telo Genomics Corp released its earnings results on Jun 02, 2026. The company reported -C$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.006.
Is Telo Genomics Corp overvalued?
According to Wall Street analysts Telo Genomics Corp’s price is currently Overvalued.
Does Telo Genomics Corp pay dividends?
Telo Genomics Corp does not currently pay dividends.
What is Telo Genomics Corp’s EPS estimate?
Telo Genomics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Telo Genomics Corp have?
Telo Genomics Corp has 100,430,470 shares outstanding.
What happened to Telo Genomics Corp’s price movement after its last earnings report?
Telo Genomics Corp reported an EPS of -C$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Telo Genomics Corp?
Currently, no hedge funds are holding shares in TSE:TELO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Telo Genomics Corp
Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health conditions. The company's primary innovation is a sophisticated telomere analysis platform, which serves both to diagnose diseases and to forecast patient outcomes. This technology, often integrated with liquid biopsies, provides crucial insights for applications in both cancer and neurological illnesses. Their leading product, Telo-MM, is specifically designed to arm medical professionals with vital, actionable information for effectively managing Multiple Myeloma, a serious blood cancer. Additionally, Telo Genomics offers TeloView, a proprietary software system capable of precisely measuring individual patient telomere characteristics. Telo Genomics caters to a broad spectrum of clients, including diagnostic pathologists, clinical doctors, academic researchers, and pharmaceutical developers. A notable endorsement of its technology is a collaborative agreement with the renowned Mayo Clinic, aimed at validating the Telo-MM diagnostic tests for multiple myeloma. Founded in 2014 and based in Toronto, Canada, the company adopted its current name, Telo Genomics Corp., in April 2019, having previously operated as 3D Signatures Inc.
Technical Analysis
BioMark Diagnostics
―
StageZero Life Sciences Ltd
―
Kane Biotech
―
Sona Nanotech Inc
―
Avricore Health
―